IGC Pharma, Inc.
IGCNext catalyst
IGC-AD1-Active
Alzheimer Disease
Get an email about IGC's next catalysts
Track IGC Pharma (IGC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
IGC Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.02 | FQ end Sep/2026 | Call: tbd
IGC-AD1-Active Phase 2 Est. Readout
Primary completion for IGC-AD1-Active trial (NCT05543681) in Alzheimer Disease
SourcePhase 2 — CALMA
For Alzheimer's. IGC Pharma is strengthening regulatory readiness as its Phase 2 CALMA Alzheimer's trial approaches enrollment closure with a Q4 topline readout expected.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IGC-AD1-Active | Phase 2 | Alzheimer Disease | - | - |
Frequently asked questions
What is in IGC Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in IGC Pharma, Inc.'s (IGC) pipeline across Phase 2. Its lead program is IGC-AD1-Active (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IGC Pharma, Inc.'s next FDA catalyst?→
IGC Pharma, Inc.'s (IGC) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IGC biotech catalysts?→
Add IGC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IGC Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.